Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
N Engl J Med. 2022.
PMID: 35443106
Free PMC article.
Clinical Trial.
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221.
Havlir DV, et al.
N Engl J Med. 2011 Oct 20;365(16):1482-91. doi: 10.1056/NEJMoa1013607.
N Engl J Med. 2011.
PMID: 22010914
Free PMC article.
Clinical Trial.
Item in Clipboard
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Levin MJ, Ustianowski A, De Wit S, Beavon R, Thissen J, Seegobin S, Dey K, Near KA, Streicher K, Kiazand A, Esser MT.
Levin MJ, et al. Among authors: near ka.
Infect Dis Ther. 2024 May 4. doi: 10.1007/s40121-024-00970-x. Online ahead of print.
Infect Dis Ther. 2024.
PMID: 38703336
Item in Clipboard
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; COVID-19 Study to Optimally Reduce Morbidity in CareHomes and Sites with Enhanced Risk (STORMCHASER) Study Group.
Levin MJ, et al. Among authors: near ka.
Clin Infect Dis. 2023 Apr 3;76(7):1247-1256. doi: 10.1093/cid/ciac899.
Clin Infect Dis. 2023.
PMID: 36411267
Free PMC article.
Clinical Trial.
Item in Clipboard
Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.
Near KA, Stowers AW, Jankovic D, Kaslow DC.
Near KA, et al.
Infect Immun. 2002 Feb;70(2):692-701. doi: 10.1128/IAI.70.2.692-701.2002.
Infect Immun. 2002.
PMID: 11796601
Free PMC article.
Item in Clipboard
Malaria infection induces virus expression in human immunodeficiency virus transgenic mice by CD4 T cell-dependent immune activation.
Freitag C, Chougnet C, Schito M, Near KA, Shearer GM, Li C, Langhorne J, Sher A.
Freitag C, et al. Among authors: near ka.
J Infect Dis. 2001 Apr 15;183(8):1260-8. doi: 10.1086/319686. Epub 2001 Mar 9.
J Infect Dis. 2001.
PMID: 11262209
Item in Clipboard
Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis.
Near KA, Lefford MJ.
Near KA, et al.
J Clin Microbiol. 1992 May;30(5):1105-10. doi: 10.1128/jcm.30.5.1105-1110.1992.
J Clin Microbiol. 1992.
PMID: 1583106
Free PMC article.
Item in Clipboard
Long term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage.
Ehrenreich H, Lange M, Near KA, Anneser F, Schoeller LA, Schmid R, Winkler PA, Kehrl JH, Schmiedek P, Goebel FD.
Ehrenreich H, et al. Among authors: near ka.
Res Exp Med (Berl). 1992;192(4):257-68. doi: 10.1007/BF02576282.
Res Exp Med (Berl). 1992.
PMID: 1410800
Item in Clipboard
Cite
Cite